Chris Schott
Stock Analyst at JP Morgan
(3.55)
# 859
Out of 4,944 analysts
133
Total ratings
56.18%
Success rate
3.06%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRGO Perrigo Company | Maintains: Overweight | $38 → $35 | $23.66 | +47.93% | 12 | Aug 7, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $550 → $675 | $663.92 | +1.67% | 8 | Aug 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $950 → $800 | $561.55 | +42.46% | 8 | Jun 9, 2025 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Overweight | $21 → $23 | $17.21 | +33.64% | 16 | May 12, 2025 | |
| BIIB Biogen | Maintains: Neutral | $185 → $175 | $135.19 | +29.45% | 4 | May 5, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $120 → $130 | $120.14 | +8.21% | 6 | Mar 27, 2025 | |
| AMRX Amneal Pharmaceuticals | Upgrades: Overweight | $9 → $12 | $9.40 | +27.66% | 2 | Feb 24, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $210 → $200 | $201.47 | -0.73% | 2 | Nov 13, 2024 | |
| ZTS Zoetis | Maintains: Overweight | $225 → $230 | $152.44 | +50.88% | 2 | Oct 11, 2024 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,050 → $1,100 | $660.49 | +66.54% | 20 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $18 → $20 | $9.36 | +113.68% | 2 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $36.46 | +15.19% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $289.33 | -6.68% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $25.16 | +35.14% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $82.71 | +51.13% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $10.41 | +34.49% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $1.00 | +1,001.10% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $20 | $17.81 | +12.30% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.17 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $47.85 | +63.01% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $7.87 | +11,971.16% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.14 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $24.96 | +100.36% | 3 | Nov 2, 2018 |
Perrigo Company
Aug 7, 2025
Maintains: Overweight
Price Target: $38 → $35
Current: $23.66
Upside: +47.93%
IDEXX Laboratories
Aug 4, 2025
Maintains: Overweight
Price Target: $550 → $675
Current: $663.92
Upside: +1.67%
Regeneron Pharmaceuticals
Jun 9, 2025
Maintains: Overweight
Price Target: $950 → $800
Current: $561.55
Upside: +42.46%
Teva Pharmaceutical Industries
May 12, 2025
Upgrades: Overweight
Price Target: $21 → $23
Current: $17.21
Upside: +33.64%
Biogen
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $135.19
Upside: +29.45%
Gilead Sciences
Mar 27, 2025
Maintains: Overweight
Price Target: $120 → $130
Current: $120.14
Upside: +8.21%
Amneal Pharmaceuticals
Feb 24, 2025
Upgrades: Overweight
Price Target: $9 → $12
Current: $9.40
Upside: +27.66%
AbbVie
Nov 13, 2024
Maintains: Overweight
Price Target: $210 → $200
Current: $201.47
Upside: -0.73%
Zoetis
Oct 11, 2024
Maintains: Overweight
Price Target: $225 → $230
Current: $152.44
Upside: +50.88%
Eli Lilly and Company
Sep 13, 2024
Maintains: Overweight
Price Target: $1,050 → $1,100
Current: $660.49
Upside: +66.54%
Sep 6, 2024
Downgrades: Underweight
Price Target: $18 → $20
Current: $9.36
Upside: +113.68%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $36.46
Upside: +15.19%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $289.33
Upside: -6.68%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $25.16
Upside: +35.14%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $82.71
Upside: +51.13%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $10.41
Upside: +34.49%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.00
Upside: +1,001.10%
Oct 17, 2022
Maintains: Neutral
Price Target: $24 → $20
Current: $17.81
Upside: +12.30%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $7.17
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $47.85
Upside: +63.01%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $7.87
Upside: +11,971.16%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.14
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $24.96
Upside: +100.36%